Ironwood Pharma (IRWD) Misses Q2 EPS by $6.96; Offers FY23 Revenue Guidance

Ironwood Pharma (NASDAQ: IRWD) reported Q2 EPS of ($6.71), $6.96 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $107.38 million versus the consensus estimate of $103.57 million.

GUIDANCE:

Ironwood Pharma sees FY2023 revenue of $435-450 million, versus the consensus of $427.9 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Robinhood prices $2B convertible notes offering due 2029
• Ennis (EBF) Reports In-Line Q1 EPS